Form 4: Elanco Animal Health CEO Acquires Deferred Stock Units

Jeffrey N. Simmons, CEO of Elanco Animal Health, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Summary

• On April 18, 2025, Jeffrey N. Simmons, the CEO and a director of Elanco Animal Health Inc., acquired 326.5613 deferred stock units.
• These units represent the right to receive one share of Elanco common stock or the cash equivalent.
• The price of the derivative security was $8.48.
• Following the transaction, Simmons beneficially owns 15,750.7319 deferred stock units directly.
• The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and insider confidence.

Positives

• The acquisition of deferred stock units by the CEO demonstrates confidence in the company's future performance.

Future Outlook

The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Industry Context

Executive compensation through deferred stock units is a common practice in the animal health industry to align management's interests with those of shareholders.

Stakeholder Impact

• The acquisition of deferred stock units by the CEO aligns his interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

Elanco Animal Health, Jeffrey N. Simmons, deferred stock units, Form 4, SEC filing, executive compensation, stock match plan